13:59 , Apr 9, 2019 |  BC Extra  |  Company News

BeiGene, BioAtla in deal for conditionally activated CTLA-4 inhibitor

BioAtla granted BeiGene a license to BA3071 (CAB-CTLA-4), a conditionally activated inhibitor of CTLA-4, that the partners will develop jointly to treat cancer. The companies plan to test the mAb as monotherapy and in combination...
00:04 , Apr 6, 2019 |  BioCentury  |  Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
10:30 , Apr 1, 2019 |  BC Extra  |  Financial News

SpringWorks raises $125M series B round

A year and a half after raising its initial round of funding to develop programs spun out of Pfizer, SpringWorks has raised $125 million in a series B round. The company now has funding to...
17:30 , Mar 8, 2019 |  BC Week In Review  |  Company News

BeiGene, Ambrx partner to discover, develop cancer biologics

BeiGene partnered with Ambrx to discover cancer therapeutics using the latter's site-specific conjugation technology. The technology uses cell lines engineered with transfer RNAs (tRNAs)/tRNA synthase that can incorporate non-natural amino acids into specified peptide and...
01:42 , Mar 1, 2019 |  BC Week In Review  |  Company News

Celgene products drive BeiGene 4Q revenue gains

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) reported its 4Q18 earnings late Feb. 27 with revenue gains driven by its in-licensed products from Celgene Corp. (NASDAQ:CELG). BeiGene's portfolio includes Chinese rights to cancer drugs Abraxane nab-paclitaxel, Revlimid lenalidomide...
02:40 , Feb 28, 2019 |  BC Week In Review  |  Financial News

CStone raises $285M in Hong Kong IPO

CStone Pharmaceuticals Co. Ltd. (HKSE:2616) priced its IPO on the Hong Kong stock exchange Feb. 25, raising HK$2.2 billion (US$285 million). The oncology company rose HK$0.86 to HK$12.86 in its first day of trading Feb....
00:50 , Feb 28, 2019 |  BC Extra  |  Financial News

Celgene products drive BeiGene 4Q revenue gains

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) reported its 4Q18 earnings late Wednesday with revenue gains driven by its in-licensed products from Celgene Corp. (NASDAQ:CELG). BeiGene's portfolio includes Chinese rights to cancer drugs Abraxane nab-paclitaxel, Revlimid lenalidomide and...
15:01 , Feb 26, 2019 |  BC Extra  |  Financial News

First-day gain for CStone on Hong Kong exchange

CStone Pharmaceuticals Co. Ltd. (HKSE:2616) rose HK$0.86 to HK$12.86 in its first day of trading Tuesday after raising HK$2.2 billion ($285 million) in its IPO. The oncology company priced the offering early Monday near the...
05:32 , Feb 25, 2019 |  BC Extra  |  Financial News

CStone raises $285M in Hong Kong IPO

CStone Pharmaceuticals Co. Ltd. (HKSE:2616) priced its IPO on the Hong Kong stock exchange early Monday, raising HK$2.2 billion (US$285 million). The offering values CStone at HK$11.8 billion (US$1.5 billion). CStone sold 18.6 million shares...
22:10 , Jan 25, 2019 |  BC Extra  |  Company News

Management Tracks: Zealand, BeiGene

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said EVP and Chief Medical and Development Officer Adam Steensberg will become interim CEO on March 1. He will succeed Britt Meelby Jensen, who is leaving the company on Feb....